Compare TENX & CTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TENX | CTM |
|---|---|---|
| Founded | 1967 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.8M | 63.1M |
| IPO Year | 2001 | 2022 |
| Metric | TENX | CTM |
|---|---|---|
| Price | $1.48 | $0.42 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $10.29 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 545.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.33 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $52,866,001.00 |
| Revenue This Year | N/A | $4.94 |
| Revenue Next Year | N/A | $8.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.10 |
| 52 Week Low | $1.31 | $0.34 |
| 52 Week High | $19.40 | $1.24 |
| Indicator | TENX | CTM |
|---|---|---|
| Relative Strength Index (RSI) | 35.62 | 37.58 |
| Support Level | $1.34 | $0.34 |
| Resistance Level | $2.01 | $0.66 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 6.25 | 41.41 |
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Castellum Inc is focused on building a successful technology services, solutions, and products company in the areas of cybersecurity, IT, electronic warfare, information warfare, system modernization, and information operations with businesses in the defense, federal, civilian, and commercial markets. Services include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and model-based systems engineering. The company maintains one operating and reportable segment, which is the delivery of products and services in the areas of information technology, electronic warfare, information warfare and cybersecurity in the governmental and commercial markets.